Implementing a Phase II Ebola Vaccine Trial in Burkina Faso

Houreratou Barry¹, Innocent Valéa¹, Halidou Tinto¹², Rodolphe Thiébaut³, Nicolas Meda¹⁴ and Cynthia Robinson⁵

¹Centre MURAZ, Bobo-Dioulasso, Burkina Faso; ²Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé, Ouagadougou; ³Institut de Santé Publique, d’Epidémiologie et de Développement (ISPED), Université de Bordeaux; ⁴Université de Ouaga I Pr. Joseph Ky-Zerbo, Ouagadougou, Burkina Faso; ⁵Janssen Vaccines and Prevention

**Facts & Figures**

| Start date: | 01/12/ 2014 |
| End date: | 30/11/ 2019 |

**Contributions**

- IMI funding: 22 790 820 €
- EFPIA in kind: 27 920 073 €
- Other: 0 €

**Total Cost**: 50 710 893 €

**Project website**: www.ebovac2.com

**Challenge**

During the West African Ebola outbreak in 2013, the international community faced the challenge of implementing trials during health emergency in Africa. The Ebovac2 consortium was setup to conduct a phase 2 vaccine trial with the support of IMI.

**Case Description**

Within one year, a fully well-equipped, GCP compliant clinical trial facility was set up at Centre MURAZ, Bobo-Dioulasso, Burkina Faso. The laboratory was equipped and the staff was trained on Peripheral Blood Mononuclear Cells isolation for cellular immune response characterisation. The clinical trial staff was trained in GCP and GCLP.

**Outcomes**

- Successful conduct of a phase 2 Ebola vaccine trial,
- 218 participants (121 healthy adults, 36 people living with HIV, 26 adolescents and 35 children) enrolled and vaccinated,
- Contribution to consortium’s overall goals achievement.

**Value of IMI collaboration**

- Strengthening of Centre MURAZ clinical research capacities beyond drugs trials and covering today vaccines trials,
- Establishment of a new clinical trials networking partner in West-Africa for future research activities.

**Impact & take home message**

- This experience has shown that capacity building should be done prior to emergency situations to allow readiness of research centres for rapid response in terms of trials conduct when needed;
- Capacity building of trial sites should be integrated by sponsors as part of their responsibilities in their collaborations with developing countries.